IDH305 is under clinical evaluation as a single agent or in combination with standard treatments for the therapy of patients with progressive II or III gliomas, low-grade gliomas with measurable 2-HG levels, AML, and other advanced malignancies harboring IDH1/R132H mutations (see summary in Table 1). The gene discussed is IDH1; the disease is glioma.